Keep it serious about investing in NVLX-
There are reasons you’re watching this board on Nuvilex, and not just for the quick pop we’ve seen since the start of the week. The recent update from Rob Goldman is worth reading if you’re not sure where this one is heading and where to expect the pop-producing milestones to occur. Pay close note also to Goldman’s pointing out just why NVLX will remain a target for short sellers and whatever tactics they can muster over the next several months leading up to the beginning of the Phase III clinical trials.
In just the last couple of weeks, two negative reports appeared on the well read Seeking Alfa website alone. As holders of NVLX, you need to question who are they written by, do these authors typically write about development stage microcaps like NVLX, and most importantly, is there an underlying agenda that they are attempting to drive down the throats of small investors in order to panic them into premature selling? Such was the intent of the two Seeking Alfa articles bashing NVLX. Guaranteed, you’ll see more of this type of article in the coming months.
Investor Tip: if you are reading a report that appears to represent a detailed, if not serious breakdown on a stock, especially microcaps, look for their DISCLOSURE. If it is not there, you are not reading a valid analysis, that is, one that you should trust, despite whatever credentials the author may lay claim to.
A good example: OTC Journal is one of the “promoters” referenced in last week’s Seeking Alfa piece. But did the author mention that OTC Journal (Larry Isen, editor) has not been compensated by NVLX in more than a year? Instead, he continues to hold shares, as many of you are doing, while providing coverage of NVLX through OTC. That makes a difference, and drives home my point about understanding agendas on the part of these self-described experts promoting the agenda of the short sellers.
FYI-over the next two weeks, OTC Journal will be interviewing several of the CEOs whose stocks they cover, including the Nuvilex CEO Dr. Rob Ryan. Dr. Ryan and Nuvilex have been remarkably candid in their previous interviews. Could be worth watching out for among current, nervous, and potential investors (otcjournal.com).
For heaven’s sake, be smart, don’t hit those panic buttons, like we saw last week, and least with Nuvilex, look to be buying when others are unwisely reacting to the inevitable bashing an attention garnering stock like NVLX will generate.
DISCLOSURE: I am a stock holder of NVLX and intend to hold for the long-term.
